Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Red blood cell (RBC) adhesion molecules are a group of cell surface proteins that mediate the attachment of RBCs to other cells, extracellular matrix components, or the vascular endothelium. These molecules, including BCAM/Lu, ICAM-4, and CD36, play a critical role in the pathophysiology of diseases such as sickle cell disease and malaria, where abnormal RBC adhesion contributes to vaso-occlusion and endothelial damage. Targeting these adhesion molecules represents a potential therapeutic strategy for preventing vascular complications in these diseases.
Inhibition of RBC adhesion to endothelium or extracellular matrix.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Red Blood Cell Adhesion Molecules (RBC Adhesion Molecules).